Studies from Affiliated Hospital of Hangzhou Normal University Add New Findings in the Area of Sodium-Glucose Transporter 2 Inhibitors (Investigating the impact of empagliflozin on the retina of diabetic mice).

A study conducted at the Affiliated Hospital of Hangzhou Normal University investigated the impact of empagliflozin, a sodium-glucose transporter 2 (SGLT2) inhibitor, on the retina of diabetic mice. The study aimed to explore the potential role of empagliflozin in preventing and delaying diabetic retinopathy (DR). The results showed that empagliflozin reduced blood glucose levels, inflammatory factors, and vascular endothelial growth factor (VEGF) levels in the eyes of diabetic mice. It also preserved the blood-retinal barrier (BRB) structure and function. The study suggests that empagliflozin may be effective in preventing or treating DR. [Extracted from the article]